Replies to post #111672 on Anavex Life Sciences Corp (AVXL)

[rocalinda]

Dude,

At least do some DD before posting stuff.

The biotech's big sell revolves around azeliragon, which Pfizer dumped after a trial using a 20-mg dose was stopped after signs of cognitive worsening developed in patients. But the company, run by Stephen Holcombe with former Pfizer CEO Jeff Kindler acting as executive chairman--says the 5-mg dose demonstrated an improvement for a key ADAS-Cog score on cognition, and that's the window it's shooting for among patients with a mild form of the disease.

"This is a very, very tight window between what could be a good effect and what is certainly a very bad one," noted biotech blogger Derek Lowe, "which is surely why Pfizer dropped the compound like it was giving off gamma rays and has not returned to it."

[The Mongoose]

Just curious, not meant to be a poke or anything but honestly Amateur, are you invested in AVXL? I'm not quite sure I understand your position? I don't think I have ever read a positive post from you? So either you love AVXL like the guy who heckled wild thing in the movie major league or your just hear to spread FUD...which one is it? I appreciate DD and different perspectives but what exact is yours and why do you continue to hang around AVXL if your so critical when we aren't even in P3 yet?

[Investor2014]

VTv is interesting also for their approach to diabetes, but as a stock it has done worse than AVXL.